A Phase II/III Randomized Trial of Two Doses of MK-3475 (SCH900475) Versus Docetaxel in Previously Treated Subjects With Non-Small Cell Lung Cancer

Trial Profile

A Phase II/III Randomized Trial of Two Doses of MK-3475 (SCH900475) Versus Docetaxel in Previously Treated Subjects With Non-Small Cell Lung Cancer

Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 13 Jul 2017

At a glance

  • Drugs Pembrolizumab (Primary) ; Docetaxel
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms KEYNOTE-010
  • Sponsors Merck & Co; Merck Sharp & Dohme
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 06 Jun 2017 Results weighing and comparing cost and value of Nivolumab, Atezolizumab and Pembrolizumab vs. Docetaxel using patient data from KEYNOTE-010, POPLAR, Checkmate 057, Checkmate-017 and one other trial, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 06 Jun 2017 Results (Data cut off September 30, 2016) assessing factors associated with better overall survival, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top